猪沙门菌转运鸡GM-CSF和鸡IL-18真核表达质粒的实验研究
|
摘要
猪霍乱沙门菌C500弱毒株是预防仔猪副伤寒的高效、安全的疫苗株。用其作载体,将含外源基因的真核表达质粒携带到宿主体内并表达外源蛋白,激活免疫系统,引起免疫反应。其独特的优点体现在既可作为针对沙门菌抗原的活疫苗,也可作为外源基因的活载体,并以其菌体成份的佐剂属性,增强机体的免疫应答反应。
本实验利用DNA重组技术将鸡粒/巨噬细胞集落刺激因子基因(CGM-CSF)与鸡白细胞介素18基因(CIL-18),克隆到真核表达载体pVAX1上,构建得到真核表达质粒pVAX1-CGMCSF:pVAX1-CIL18;pVAX1-CGMCSF/CIL-18。并将这3种质粒以及空质粒pVAX1分别转化C500菌。通过将C500(pVAX1-CGMCSF/CIL-18)和C500(pVAX1)体外培养和体内接种的方法,研究该真核表达质粒在体外和体内的稳定性,以及重组菌在体内的消长动态。同时将重组菌C500(pVAX1-CGMCSF/CIL-18)和C500(pVAX1)分别以10~8、10~9、10~(10)CFU/只的剂量口服接种雏鸡,并在雏鸡体内传代接种的方法,研究该重组菌对雏鸡的安全性。结果显示重组菌在体外培养过程中,外界无抗性选择压力条件下,所携带质粒在重组菌中的稳定性也会随之降低。外界有抗性选择压力条件下,所携带质粒在重组菌传代过程中的稳定性于第8代后出现下降明显的趋势。在体内接种过程中,粪便分离菌通过酶切鉴定,血液,肝脏,脾脏,肠道粘膜所提DNA通过PCR鉴定均能获得清晰的目的条带,表明重组菌能将目的基因转运机体细胞内。
将重组菌C500(pVAX1-CGMCSF/CIL-18)和C500(pVAX1)以10~9CFU/只剂量口服接种雏鸡后,分别从脏器指数、鸡脾细胞增殖试验和碳粒廓清指数三个方面检测重组菌免疫后对雏鸡免疫功能的影响,结果显示了免疫功能指标均呈现重组菌C500(pVAX1-CGMCSF/CIL-18)组高于重组菌C500(pVAX1)组并显著高于对照组(p＜0.05),表明重组菌接种后,进入体内释放出真核表达质粒,并能表达外源基因,促进雏鸡免疫器官的发育,提高机体的免疫功能。
在此基础上,将C500(pVAX1);C500(pVAX1-CGMCSF);C500(pVAX1-CIL18):C500(pVAX1-CGMCSF/CIL-18)分别免疫4组雏鸡,每组10只,于重组菌接种后1周各组以0.2ml/羽的剂量颈部皮下注射禽流感油乳剂灭活苗,设立PBS+灭活苗对照组,分别于免疫前、免疫后每隔1周翅静脉采血,通过间接血凝抑制试验检测血清抗体血凝抑制效价。结果显示了C500(pVAX1);C500(pVAX1-CGMCSF):C500(pVAX1-CIL18);C500(pVAX1-CGMCSF/CIL-18)均能提高鸡群免疫灭活苗后的抗体效价,免疫后7天、14天、21天、28天C500(pVAX1-CGMCSF/CIL-18)组的血凝抑制效价均显著高于PBS对照组(P＜0.05);C500(pVAX1-CGMCSF)组和C500(pVAX1-CIL18)组在免疫后7天、14天、21天血凝抑制效价显著高于PBS对照组(P＜0.05),免疫后28天差异均不显著(P＞0.05)。表明用猪霍乱沙门菌C500弱毒株能将基因转运至机体内,携带的GM-CSF,IL-18可有效提高鸡的免疫功能和抗体水平,发挥了细胞因子GM-CSF和IL-18的免疫佐剂作用,为细胞因子之间的协同作用提供了实践依据。
Attenuated choleraesuis salmonella C500 is efficient and secure vaccine strains for preventing piglet paratyphoid.As the vector,carrying eukaryotic expression plasmid which is containd foreign gene to the host and expressing exogenous protein will activate immune system and cause immune response.Its distinctive advantages are not only acting as live vaccine which is aiming at salmonella antigen,but also acting as live vector of foreign gene,and strengthen the organism's immune response by its quality of adjuvant that it is the component of bacteria.
This experiment clones the gene of chicken granulocyte / macrophage colonystimulating factor(CGM-CSF) and chicken interleukin-18(CIL-18) to the eukaryotic expression vector of pVAX1 by recombinant PCR technology,and with this construction, get the eukaryotic expression plasmids such as pVAX1-CGMCSF,pVAX1-CIL-18,pVAX1-CGMCSF/CIL-18.Getting eukaryotic expression plasmid into salmonella choleraesuis by the reorganization of conversion technology,we can construct these recombinant bacteria as C500(pVAX1),C500(pVAX1-CGMCSF),C500 (pVAX1-CIL18),C500(pVAX1-CGMCSF/CIL-18).This experiment researches the stability of the eukaryotic expression plasmid C500(pVAX1-CGMCSF/CIL-18)and C500(pVAX1),the dynamics of recombinant bacteria in vivo by the method of getting C500(pVAX1-CGMCSF/CIL-18) and C500(pVAX1) foster in vitro and vaccinate in vivo.At the same time,this experiment also researches the security of the recombinant bacteria for young chicken by the method of inoculating from generation to generation in the young chicken that is vaccinating young chicken orally with the recombinant bacteria C500(pVAX1-CGMCSF/CIL-18) and C500(pVAX1) by the dosage as 10~8,10~9,10~(10) CFU per chicken separately.The results shows that the stability of the plasmid which is carried by the recombinant bacteria reduces when the recombinant bacteria is in the process of fostering in vitro and the condition of outside without resistance selection pressure.When the condition of outside is with resistance selection pressure,the stability of the plasmid carded by the recombinant bacteria reduces.Obviously after the 8th in the process of fostering from generation to generation. In the prosess of vaccination in vivo,both the bacteria isolated from.Faeces that identified through the restrinction endonuclease analysis and the DNA extracted from the blood,liver,spleen and intestinal mucosa that identified through the PCR can get clear purpose strip.This shows that the recombinant bacteria can transferre the goal gene to the cells in organisms.
In view of the cytokines both GM-CSF and IL-18 are immunoregulatory factors and they can strengthen the immune function,we vaccinate the young chicken orally with the recombinant bacteria C500(pVAX1-CGMCSF/CIL-18) and C500(pVAX1) 10~9CFU per chicken.Then we detect the influence of immune function from tree aspects that organ index,chicken spleen cells proliferation test and carbon clearance index.The results show that the immune function indicators of the group which is vaccinated C500(pVAX1-CGMCSF/CIL-18) are higer than the group which is vaccinated C500(pVAX1),and significantly higher than the control group(p＜0.05).
This indicates that the recombinant bacteria vaccinated and after they get into the immune organs,they can release eukaryotic expression plasmid,express foreign gene, stimulate the immune function that against salmonella carrier and foreign gene,and promote the young chickens' immune organs growing.
On this basis,we vaccinate 4 groups with C500(pVAX1),C500(pVAX1-CGMCSF), C500(pVAX1-CIL18),C500(pVAX1-CGMCSF/CIL-18) separately and every group is 10 chickens.Then we take blood from wing vein every week respectively before immunity and after immunity,and detect the hemagglutination inhibition titer of serum antibody through indirect hemagglutination inhibition test.The result shows that C500(pVAX1),C500(pVAX1-CGMCSF),C500(pVAX1-CIL18),and C500 (pVAX1-CGMCSF/CIL-18) can all raise the Antibody titer after the chickens vaccinated inactivated vaccine.This shows that the recombinant bacteria using attenuated salmonella choleraesuis C500 as vector can raise the young chickens' antibody level which is against the avian influenza oil-emulsion inactivated vaccine effectively,it plays the function of cytokines GM-CSF and IL-18 as immune adjuvant,and it provides practice foundation for the synergy between cytokines.
本实验利用DNA重组技术将鸡粒/巨噬细胞集落刺激因子基因(CGM-CSF)与鸡白细胞介素18基因(CIL-18),克隆到真核表达载体pVAX1上,构建得到真核表达质粒pVAX1-CGMCSF:pVAX1-CIL18;pVAX1-CGMCSF/CIL-18。并将这3种质粒以及空质粒pVAX1分别转化C500菌。通过将C500(pVAX1-CGMCSF/CIL-18)和C500(pVAX1)体外培养和体内接种的方法,研究该真核表达质粒在体外和体内的稳定性,以及重组菌在体内的消长动态。同时将重组菌C500(pVAX1-CGMCSF/CIL-18)和C500(pVAX1)分别以10~8、10~9、10~(10)CFU/只的剂量口服接种雏鸡,并在雏鸡体内传代接种的方法,研究该重组菌对雏鸡的安全性。结果显示重组菌在体外培养过程中,外界无抗性选择压力条件下,所携带质粒在重组菌中的稳定性也会随之降低。外界有抗性选择压力条件下,所携带质粒在重组菌传代过程中的稳定性于第8代后出现下降明显的趋势。在体内接种过程中,粪便分离菌通过酶切鉴定,血液,肝脏,脾脏,肠道粘膜所提DNA通过PCR鉴定均能获得清晰的目的条带,表明重组菌能将目的基因转运机体细胞内。
将重组菌C500(pVAX1-CGMCSF/CIL-18)和C500(pVAX1)以10~9CFU/只剂量口服接种雏鸡后,分别从脏器指数、鸡脾细胞增殖试验和碳粒廓清指数三个方面检测重组菌免疫后对雏鸡免疫功能的影响,结果显示了免疫功能指标均呈现重组菌C500(pVAX1-CGMCSF/CIL-18)组高于重组菌C500(pVAX1)组并显著高于对照组(p＜0.05),表明重组菌接种后,进入体内释放出真核表达质粒,并能表达外源基因,促进雏鸡免疫器官的发育,提高机体的免疫功能。
在此基础上,将C500(pVAX1);C500(pVAX1-CGMCSF);C500(pVAX1-CIL18):C500(pVAX1-CGMCSF/CIL-18)分别免疫4组雏鸡,每组10只,于重组菌接种后1周各组以0.2ml/羽的剂量颈部皮下注射禽流感油乳剂灭活苗,设立PBS+灭活苗对照组,分别于免疫前、免疫后每隔1周翅静脉采血,通过间接血凝抑制试验检测血清抗体血凝抑制效价。结果显示了C500(pVAX1);C500(pVAX1-CGMCSF):C500(pVAX1-CIL18);C500(pVAX1-CGMCSF/CIL-18)均能提高鸡群免疫灭活苗后的抗体效价,免疫后7天、14天、21天、28天C500(pVAX1-CGMCSF/CIL-18)组的血凝抑制效价均显著高于PBS对照组(P＜0.05);C500(pVAX1-CGMCSF)组和C500(pVAX1-CIL18)组在免疫后7天、14天、21天血凝抑制效价显著高于PBS对照组(P＜0.05),免疫后28天差异均不显著(P＞0.05)。表明用猪霍乱沙门菌C500弱毒株能将基因转运至机体内,携带的GM-CSF,IL-18可有效提高鸡的免疫功能和抗体水平,发挥了细胞因子GM-CSF和IL-18的免疫佐剂作用,为细胞因子之间的协同作用提供了实践依据。
Attenuated choleraesuis salmonella C500 is efficient and secure vaccine strains for preventing piglet paratyphoid.As the vector,carrying eukaryotic expression plasmid which is containd foreign gene to the host and expressing exogenous protein will activate immune system and cause immune response.Its distinctive advantages are not only acting as live vaccine which is aiming at salmonella antigen,but also acting as live vector of foreign gene,and strengthen the organism's immune response by its quality of adjuvant that it is the component of bacteria.
This experiment clones the gene of chicken granulocyte / macrophage colonystimulating factor(CGM-CSF) and chicken interleukin-18(CIL-18) to the eukaryotic expression vector of pVAX1 by recombinant PCR technology,and with this construction, get the eukaryotic expression plasmids such as pVAX1-CGMCSF,pVAX1-CIL-18,pVAX1-CGMCSF/CIL-18.Getting eukaryotic expression plasmid into salmonella choleraesuis by the reorganization of conversion technology,we can construct these recombinant bacteria as C500(pVAX1),C500(pVAX1-CGMCSF),C500 (pVAX1-CIL18),C500(pVAX1-CGMCSF/CIL-18).This experiment researches the stability of the eukaryotic expression plasmid C500(pVAX1-CGMCSF/CIL-18)and C500(pVAX1),the dynamics of recombinant bacteria in vivo by the method of getting C500(pVAX1-CGMCSF/CIL-18) and C500(pVAX1) foster in vitro and vaccinate in vivo.At the same time,this experiment also researches the security of the recombinant bacteria for young chicken by the method of inoculating from generation to generation in the young chicken that is vaccinating young chicken orally with the recombinant bacteria C500(pVAX1-CGMCSF/CIL-18) and C500(pVAX1) by the dosage as 10~8,10~9,10~(10) CFU per chicken separately.The results shows that the stability of the plasmid which is carried by the recombinant bacteria reduces when the recombinant bacteria is in the process of fostering in vitro and the condition of outside without resistance selection pressure.When the condition of outside is with resistance selection pressure,the stability of the plasmid carded by the recombinant bacteria reduces.Obviously after the 8th in the process of fostering from generation to generation. In the prosess of vaccination in vivo,both the bacteria isolated from.Faeces that identified through the restrinction endonuclease analysis and the DNA extracted from the blood,liver,spleen and intestinal mucosa that identified through the PCR can get clear purpose strip.This shows that the recombinant bacteria can transferre the goal gene to the cells in organisms.
In view of the cytokines both GM-CSF and IL-18 are immunoregulatory factors and they can strengthen the immune function,we vaccinate the young chicken orally with the recombinant bacteria C500(pVAX1-CGMCSF/CIL-18) and C500(pVAX1) 10~9CFU per chicken.Then we detect the influence of immune function from tree aspects that organ index,chicken spleen cells proliferation test and carbon clearance index.The results show that the immune function indicators of the group which is vaccinated C500(pVAX1-CGMCSF/CIL-18) are higer than the group which is vaccinated C500(pVAX1),and significantly higher than the control group(p＜0.05).
This indicates that the recombinant bacteria vaccinated and after they get into the immune organs,they can release eukaryotic expression plasmid,express foreign gene, stimulate the immune function that against salmonella carrier and foreign gene,and promote the young chickens' immune organs growing.
On this basis,we vaccinate 4 groups with C500(pVAX1),C500(pVAX1-CGMCSF), C500(pVAX1-CIL18),C500(pVAX1-CGMCSF/CIL-18) separately and every group is 10 chickens.Then we take blood from wing vein every week respectively before immunity and after immunity,and detect the hemagglutination inhibition titer of serum antibody through indirect hemagglutination inhibition test.The result shows that C500(pVAX1),C500(pVAX1-CGMCSF),C500(pVAX1-CIL18),and C500 (pVAX1-CGMCSF/CIL-18) can all raise the Antibody titer after the chickens vaccinated inactivated vaccine.This shows that the recombinant bacteria using attenuated salmonella choleraesuis C500 as vector can raise the young chickens' antibody level which is against the avian influenza oil-emulsion inactivated vaccine effectively,it plays the function of cytokines GM-CSF and IL-18 as immune adjuvant,and it provides practice foundation for the synergy between cytokines.
引文
[1]Medina E,Paglia P,Nikolaus T,et al.Pathogenicity island 2 mutants of Salmonella typhi murium are efficient carriers for heterologous antigens and enable modulation of immune responses.Infect Immunity,1999,67(3):1093-1099.
[2]Urashima M,Suzuki H,Yuza Y,et al.An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhi murium.Blood,2000,95(4):1258-1263
[3]Shiau AL,Chen YL,LiaoCY et al.Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salm -onella choleraesuis[J].Vaccine,2001,19:3947-3956
[4]Shiau AL,Chen CC,YoYT et al.Enhancement of humoral and cellular immune res -ponses by an oral Salmonella choleraesuis vaccine expressing porcine prothymosin alpha[J].Vaccine,2005,23(48-49):5563-5571
[5]房晓文.仔猪副伤寒弱毒疫苗研究.研究报告汇辑,中国兽医药品监察所,1978,4:1-11
[6]黄昌炳,冯文达,薛民权等.仔猪副伤寒弱毒通气培养冻干苗口服免疫研究[J].中国农业科学,1981,6:89-94
[7]康凯.仔猪副伤寒活疫苗[J].中国兽药杂志,2003,37(2):49
[8]Ministry of Agriculture Veterinary Biological Product Regulation Committee Compiled.The People's Republic of China Veterinary Biological Product Regulation,Beijing:Chemical Industry Publishing Company.2OOO,pp.164-166
[9]Wood P R,Seow H F.T cell cytokines and diseases prevention[J].Vet Immunol Immunopathol,1996,54,33-44.
[10]高玲美,牛钟相,丁淑燕.动物细胞因子研究进展[J].动物医学进展,2003,24(4):46-48
[11]Louise S H,Andrew GD B,John WL.The emerging role of aviancytokines as immunotherapeutics and vaccine adjuvants.Veterinary Immunology and Immunopath -ology,2002,85:119-128
[12]高玲美,牛钟相,丁淑燕.动物细胞因子研究进展[J].动物医学进展,2003,24(4):46-48
[13]洪云平,文心田.细胞因子及其在兽医上的应用[J].预防兽医学进展,2000,2(2):4-7
[14]Wood P R,Seow H F.T cell cytokines and diseases prevention[J].Vet Immunol Immunopathol,1996,54,33-44.
[15]Miller-EdgeM,Splitter G A.Role of interlerkin in animals[J].In progress in veterinary M icrobiology and Immunology,1988,(4):Base1,56-87.
[16]P.G.Reddy,P.S.Mcvey,et al.Bovine recombinant granulocyte -macrophage colony-stimulating factor enhancement of bovine neutrophil functions in vitro.Am J Vet Res,1990,51(9):1395-1399
[17]Katele-A et al.Comparison of the human immune response to live oral,killed oral or killed parenteral Salmonella typhi TY21A vaccines.Micro-Pathog,1991;10(2):117.
[18]Mukkur-TK et al.Generation of aromatic-dependent Salmonella havana and evaluation of its immunogenic potential in mice and sheep.Vet-Microbiol,1991;29(2):181.
[19]E4 rysipelothrix rhusiopathiaeYS-1as a live vaccine vehicle for heterologous protein expression and intranasal immunization of pig Infect Immun 2002Jan;70(1):226-232.
[20]CD8(+)-T-cell response to secreted and nonsecreted antigens delivered by recombinant Listeria monocytogenes during secondary infection.Infect Immun 2002 Jan;70(1):226-232.
[21]Darji A,et al.Oral somatic trasgene vaccination using attenuated S.typhimur -ium(J) Cell,1997,91:765.
[22]Curtiss R 3~(rd),NakayamaK,Kelly S.M et al.Recombinant avirulent sallmonall a vaccine strains expression of cloned genes in vivo.Immunol Invest,1989, 18(1-4):583-96.
[23]Yan-ZX et al.Construction of an invertible DNA segment for improved antigen expression by a hybrid Salmonella vaccine strain.Res-Microbiol,1990;141(7-8):1003-1004.
[24]Giannasca PJ,Neutral MR,Interactions of microorganisms with intestinal M cells mucosal invasion and induction of secretory immunity[J],Infect Agents Dis,1994,10-15.
[25]Jones BD,Ghori N,Falkow S,et al.Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches[J],J Exp Med,1994,10:15.
[26]Somner EA,et al.Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19kDa domain of Plas modium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains[J].Microbiol,1999,145:221.
[27]Wolff JA,et al.Direct gene transfer into muscle[J].Vaccine,1994,12:1499.
[28]Lichtensteiger CA,VimrE R.Systemic and enteric colonization of pigs by a hilA signature-tagged mutant of Salmonella choleraesuis[J].Microb Pathog,2003,34(3):149-154
[29]BeliavskaiaVA,Timofeev I V,Perminova N G et al.Construction of an expression plasmid vector for accomplishing in vivo delivery of recombinant biologically active proteins 2 Synthesis of HBcAG in a vaccine strain of Salmonella choleraesuis[J].Mol Gen Mikrobiol Virusol,2000,(3):17-21
[30]乔红伟,孙金福,韩文瑜等.猪霍乱沙门氏菌载体介导猪瘟病毒DNA免疫研究[J].生物工程学报,2005,21(6):865-870
[31]陈陆平,韩文瑜,梁焕春.猪霍乱沙门氏菌-大肠杆菌K88ac、LT(A-B+)二联基因工程菌对仔猪的免疫保护试验.
[32]Lee C H,Wu C L,Shiau A L.Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models[J].J Gene Med,2004,6(12):1382-1393
[33]Lee C H,Wu C L,Shiau A L.Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression,delayed tumor growth and prolonged survival in the murine melanoma model[J].Cancer Gene Ther,2005,12(2):175-184
[34]Lee C H,Wu C L,Tai Y S et al.Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy[J].Mol Ther,2005,11(5):707-716
[35]Shata M T,Stevceva L,Agwale S,et al.Recent advances with recombinant bacterial vaccine vectors[J].Molecular Medicine Today,2000,6:66-70.
[36]窦永喜,景志忠,才学鹏,等.细胞因子及其应用的研究进展,中国兽医科技2005.35(3):233-23
[37]Zlotni A,Yoshie O.Chemokines:A new classification system and their role in immunity[J].Immunity,2000,12(2):121-127
[38]马大龙.细胞因子抑制剂,中国免疫学杂志,1994.10(1):61-62
[39]Acres B,Gantzer M,Remy C,et al,2005,Fusokine interleukin-2/interleukin-18,a novelpotent innate and adaptive immune stimulator with decreased toxicity.Cancer Res.65(20):9536-9546
[40]李元,陈松森,王渭池.基因工程药物[M].北京:化学工业出版社,2003,127-132.
[41]侯亚琴,刘桂林,等.细胞因子的研究进展及其应用,动物科学与动物医学 2004.21(10):10-12.
[42]金伯泉.细胞和分子免疫学[M].北京:科学出版社,2001,131-239
[43]Ryu D D,Nam D H.Recent progress in biomolecular engineering[J].Biotechnol Prog,2000,1(1):2-16
[44]Morgan R A,Anderson N.Human gene therapy.Annu Rev Biochem,1993,2:191-204
[45]Schijns V E,Classen I J.Vermeulen A A,et al.Modulation of antiviral immune responses by exogenous cytokines:effects of tumour necrosis factor alpha,interleukin-1 alpha,interleukin-2 and interferon-gamma on the immunogenictiy of an inactivated rabies vaccine[J],J Gen Virol,1994,75(1):55-63
[46]Sasaki M G,Foccacia R,Messias-Reason I J.Efficacy of granulocyte-macrophage colony-stimulating factor(GM-CSF)as a vaccine adjuvant for hepatitis B virus in patients with HIV infection[J].Vaccine,2003,21(31)4545-4549
[47]Auccoutorier J,Dupuis L,Ganne Y.Adjuvants designed for veterinary and human vaccines[J].Vaccine,2001,19(17-19):2666-2672
[48]Playfair H L and Desouza J B. Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice. Clinical Experimental Immunology. 1987, 67:5-10
[49]Heath AW, Playfair JH. Conjugation of interferon-gamma to antigen enhances its adjuvanticity [J]. Immunology. 1990, 71(3):454-456.
[50]SinJL, Kim JJ, Boyer J D, et al. In vivo modulation of vaccine-induced immune response toward a Thl phenotype increases potency and vaccine effedctiveness in a herpes simplex virus type2 mouse model . J Virol. 1999, 73:501—507
[51]Micallef MJ, Ohtsuki K, Kohno F, et al. Interferon-gamma-inducing factor enhances T helper lcytokine production by stimulated human T cell: Synergi-sm with interleukin-12 for interferon-gamma production [J].Eur J Immunol, 1996, 2(7):1647-1651
[52]Guidotti LG, Huang W K, et al. Improvement of hepatitis B virus DNA vaccines by plasmid co-expressing hepatitis B surface antigen and interleukln-18. Hepato- logy, 1998, 28:202-210
[53] Chow YH Chiang BL, Lee YL, et al. Development of Thl and Th2 population and the nature of immune responses to hepatitis B virus DNA vaccines can be. modulated by code livery of various cytokine genes, J Immunol, 1998, 160:1320-1329
[54]Iwasaki A, Stiernholm B J, Chan A K, et al, Enhancee CTL responses mediated by plasmid DNA immunogenes encoding costimulatory moleculars and cytokines[J], J Immunol, 1997, 158(10):4591-4601
[55]Sin J I, Weiner D B. Improving DNA vaccines targeting viral infection [J]. Interv -irology, 2000, 43(4-6)233-246
[56]Billaut-mulot 0, IdriorekT, Loyens M, et al. Modulation of cellular and humoral immune responses to a multipitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost[J]. Vaccine, 2001, 19(20-22):2803-2811
[57]Kimm JJ,Yang J S, Vcncort T C, et al.Modulation of antigen-specific humoral responses in Rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants [J].J, Virol, 2000, 74(7):3427-3429
[58]Barouch, D H: Santra, S. Steenbeke, T. D et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. Journal of Immunology(Baltimore).1998.161:1875-1882.
[59]蔡雷.DNA免疫的基础性研究进展及应用.国外医学免疫学分册,2001,24:122-125
[60]文艳君.增强DNA免疫效应的研究进展.国外医学免疫学分册,1999,22:320-323
[61]lrvine K R,RaoJB,Rosenberg S A.et al.Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.J Immunol,1996,156:238-245
[62]Yang S et al.Generation of retroviral vector for clinical studies using transient transfection.Hum Gene Ther,1999 Jan 1;10(1):123-32
[63]Doughrety JP et al.High mutation rate of a spleen necrosis virus-based retrovirus vector.Mol Cell Biol,1986;12:4387
[64]Louis MH et al.Internal ribosome entry sites(IRESs):reality and use.Transgrnic Res,1999;8:157
[65]J.萨姆布鲁克,E.F.弗单奇,T.曼尼阿蒂斯.分子克隆实验指南第二版[M].会冬雁,黎孟枫,译.北京:科学出版社,1992.
[66]Flasshove M et al.Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene.J Cancer Res Clinoncol,2000;126:391
[67]Martinez-Salas E,Quinto S L,and Ramos R,and Fernandez-Miragall O.IRES elements:features of the RNA structure contributing to their activity.BiOchimie,2002,84:755-763.
[68]Michael E et al.Comparison of promoter suppression in avian and murine retrovirus vectors.Nucleic Acids Res,1986;23:9381
[69]刘兵等.中国生化与分子生物学报,1999;15:699
[70]Medina E,Paglia P,Nikolaus T,et al.Pathogenicity is land-mutants of Salmonella typhi murium are efficient carriers for heterologous antigens and enable modulation of immune responses.Infect Immunity,1999,67(3):1093-1099.
[71]Urashima M,Suzuki H,Yuza Y,et al.An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhi murium.Blood,2000,95(4):1258-1263.
[72]Shiau AL,Chen YL,LiaoCY et al.Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis [J]. Vaccine,2001,19:3947-3956
[73]Sydenham M, Douce G, Bowe F, et al. Salmonella enterica serovar typhimurium surA mutants are attenuated and effective live oral vaccines[J]. Immunol, 2000, 68(3):1109-1115.
[74]Ministry of Agriculture Veterinary Biological Product Regulation Committee Compiled. The People's Republic of China Veterinary Biological Product Regulation, Beijing: ChemicalIndustry Publishing Company. 2000,pp. 164-166
[75]Dietrich G, Spreng S, Gentschev I et al. Bacterial systems for the delivery of eukary oticantigen expression vectors. Antisense NucleicAcid Drug Dev , 2000 , 10(5):391-399
[76]Hone D M. Harris A M. Chatfield S et al. Construction of genetically defined double are mutant of Salmonella typhimurine. Vaccine, 1991, 9(11):810-816.
[77]Attridge S R, Davies R, Labrooy J T. Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Vaccine. 1997, 15(2):155-162.
[78]Shata M T ,Stevceva L ,Agwale S ,et al.Recent advances with recombinant bacterial vaccine vectors (J) .Mol Med Today ,2000, 6 (2) :66-71.
[79]Roy Curtiss III. Bacterial infectious disease control by vaccine development. J.C1in. Invest. 2002, 110:1061-1066.
[80]Emil Kozarov , Naohisa Miyashita , Jacob Burks et al. Expression and Immunogenicity of Hemagglutinin A from Porphyromonas gingivalis in an Avirulent Salmonella enterica Serovar Typhimurium Vaccine Strain. Infection and Immunity, 2000, 2(68):732-739.
[81]PagliaP, Terrazzini N, SchulzeK, Guzman CA, Colombo MP. In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery. Gene Ther 2000, 10, 7(20), 1725-1730.
[82]Kohno K, Kataoka J, Ohtsuki T, et al. IFN-gamma-in-ducing factor(IGIF)is a costimulatory factor on the activation of Thl but not Th2 cells and exertsits effect in-dependently of IL-12 [J] J Immunol, 1997, 158(4):1541-1550
[83]Toka F N,Pack C D,and Rouse B T.Molecular adjuvants for mucosal immunity.ImmunolOgical Reviews,2004,199:lO0-112
[84]Dietrich G,Spreng S,Gentschev I,et al.Bacterial systems for the delivery of eukaryotic antigen expression vectors[J].Antisense Nucleic Acid Drug Dev 2000,10(5):391-399.
[85]Hormaeche C E.Live attenuated Salmonella vaccines and their potential as oral combined vaccines carrying heterologous antigens[J].J Immunol Methods,19,142(1):113-120.
[86]Toebe CS,et al.Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1[J]Am J Trop Med Hyg,1997,56:192.
[87]Somner EA,et al.Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains[J]Microbiol,1999,145:221.
[88]Okamura H,Nagate K,Komatsu T,A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock[J].Infect Immun,1995,63(10):3966-3972
[89]Hilton LS,Bean AG,Lowenthal JW.The emerging role of avian cytokines as immuneotherapeutics and vaccine adjuvants[J].Vet Immunol immunopathol,2002,85(3-4):119-128
[90]洪云平,文心田.细胞因子及其在兽医上的应用[J].预防兽医学进展,2000,2(2):4-7
[91]Wood P R,Seow H F.T cell cytokines and diseases prevention[J].Vet Immunol Immunopathol,1996,54,33-44.:
[92]Johnson M A,Pooley C,Lowenthal J W.Delivery of avian cytokines by adenovirus vectors.Dev Comp Immunol,2000,24:343-354
[93]Lowenthal J W,York J J,O' Nell T E,Rhodes S,Prowse S J,Strom A D G,Digby M R.In vivo effects of chicken interferon gamma during infection with Eimeria.J Interferon Cytokine Res,1997,17:551-558
[94]Marcus P I,vander Heide L,Sekellick M J.Interferon action on avian viruses.I.Oral administration of chicken interferon-alpha ameliorates Newcastle disease.J Interferon Cytokine Res,1999,19:881-885
[2]Urashima M,Suzuki H,Yuza Y,et al.An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhi murium.Blood,2000,95(4):1258-1263
[3]Shiau AL,Chen YL,LiaoCY et al.Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salm -onella choleraesuis[J].Vaccine,2001,19:3947-3956
[4]Shiau AL,Chen CC,YoYT et al.Enhancement of humoral and cellular immune res -ponses by an oral Salmonella choleraesuis vaccine expressing porcine prothymosin alpha[J].Vaccine,2005,23(48-49):5563-5571
[5]房晓文.仔猪副伤寒弱毒疫苗研究.研究报告汇辑,中国兽医药品监察所,1978,4:1-11
[6]黄昌炳,冯文达,薛民权等.仔猪副伤寒弱毒通气培养冻干苗口服免疫研究[J].中国农业科学,1981,6:89-94
[7]康凯.仔猪副伤寒活疫苗[J].中国兽药杂志,2003,37(2):49
[8]Ministry of Agriculture Veterinary Biological Product Regulation Committee Compiled.The People's Republic of China Veterinary Biological Product Regulation,Beijing:Chemical Industry Publishing Company.2OOO,pp.164-166
[9]Wood P R,Seow H F.T cell cytokines and diseases prevention[J].Vet Immunol Immunopathol,1996,54,33-44.
[10]高玲美,牛钟相,丁淑燕.动物细胞因子研究进展[J].动物医学进展,2003,24(4):46-48
[11]Louise S H,Andrew GD B,John WL.The emerging role of aviancytokines as immunotherapeutics and vaccine adjuvants.Veterinary Immunology and Immunopath -ology,2002,85:119-128
[12]高玲美,牛钟相,丁淑燕.动物细胞因子研究进展[J].动物医学进展,2003,24(4):46-48
[13]洪云平,文心田.细胞因子及其在兽医上的应用[J].预防兽医学进展,2000,2(2):4-7
[14]Wood P R,Seow H F.T cell cytokines and diseases prevention[J].Vet Immunol Immunopathol,1996,54,33-44.
[15]Miller-EdgeM,Splitter G A.Role of interlerkin in animals[J].In progress in veterinary M icrobiology and Immunology,1988,(4):Base1,56-87.
[16]P.G.Reddy,P.S.Mcvey,et al.Bovine recombinant granulocyte -macrophage colony-stimulating factor enhancement of bovine neutrophil functions in vitro.Am J Vet Res,1990,51(9):1395-1399
[17]Katele-A et al.Comparison of the human immune response to live oral,killed oral or killed parenteral Salmonella typhi TY21A vaccines.Micro-Pathog,1991;10(2):117.
[18]Mukkur-TK et al.Generation of aromatic-dependent Salmonella havana and evaluation of its immunogenic potential in mice and sheep.Vet-Microbiol,1991;29(2):181.
[19]E4 rysipelothrix rhusiopathiaeYS-1as a live vaccine vehicle for heterologous protein expression and intranasal immunization of pig Infect Immun 2002Jan;70(1):226-232.
[20]CD8(+)-T-cell response to secreted and nonsecreted antigens delivered by recombinant Listeria monocytogenes during secondary infection.Infect Immun 2002 Jan;70(1):226-232.
[21]Darji A,et al.Oral somatic trasgene vaccination using attenuated S.typhimur -ium(J) Cell,1997,91:765.
[22]Curtiss R 3~(rd),NakayamaK,Kelly S.M et al.Recombinant avirulent sallmonall a vaccine strains expression of cloned genes in vivo.Immunol Invest,1989, 18(1-4):583-96.
[23]Yan-ZX et al.Construction of an invertible DNA segment for improved antigen expression by a hybrid Salmonella vaccine strain.Res-Microbiol,1990;141(7-8):1003-1004.
[24]Giannasca PJ,Neutral MR,Interactions of microorganisms with intestinal M cells mucosal invasion and induction of secretory immunity[J],Infect Agents Dis,1994,10-15.
[25]Jones BD,Ghori N,Falkow S,et al.Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches[J],J Exp Med,1994,10:15.
[26]Somner EA,et al.Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19kDa domain of Plas modium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains[J].Microbiol,1999,145:221.
[27]Wolff JA,et al.Direct gene transfer into muscle[J].Vaccine,1994,12:1499.
[28]Lichtensteiger CA,VimrE R.Systemic and enteric colonization of pigs by a hilA signature-tagged mutant of Salmonella choleraesuis[J].Microb Pathog,2003,34(3):149-154
[29]BeliavskaiaVA,Timofeev I V,Perminova N G et al.Construction of an expression plasmid vector for accomplishing in vivo delivery of recombinant biologically active proteins 2 Synthesis of HBcAG in a vaccine strain of Salmonella choleraesuis[J].Mol Gen Mikrobiol Virusol,2000,(3):17-21
[30]乔红伟,孙金福,韩文瑜等.猪霍乱沙门氏菌载体介导猪瘟病毒DNA免疫研究[J].生物工程学报,2005,21(6):865-870
[31]陈陆平,韩文瑜,梁焕春.猪霍乱沙门氏菌-大肠杆菌K88ac、LT(A-B+)二联基因工程菌对仔猪的免疫保护试验.
[32]Lee C H,Wu C L,Shiau A L.Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models[J].J Gene Med,2004,6(12):1382-1393
[33]Lee C H,Wu C L,Shiau A L.Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression,delayed tumor growth and prolonged survival in the murine melanoma model[J].Cancer Gene Ther,2005,12(2):175-184
[34]Lee C H,Wu C L,Tai Y S et al.Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy[J].Mol Ther,2005,11(5):707-716
[35]Shata M T,Stevceva L,Agwale S,et al.Recent advances with recombinant bacterial vaccine vectors[J].Molecular Medicine Today,2000,6:66-70.
[36]窦永喜,景志忠,才学鹏,等.细胞因子及其应用的研究进展,中国兽医科技2005.35(3):233-23
[37]Zlotni A,Yoshie O.Chemokines:A new classification system and their role in immunity[J].Immunity,2000,12(2):121-127
[38]马大龙.细胞因子抑制剂,中国免疫学杂志,1994.10(1):61-62
[39]Acres B,Gantzer M,Remy C,et al,2005,Fusokine interleukin-2/interleukin-18,a novelpotent innate and adaptive immune stimulator with decreased toxicity.Cancer Res.65(20):9536-9546
[40]李元,陈松森,王渭池.基因工程药物[M].北京:化学工业出版社,2003,127-132.
[41]侯亚琴,刘桂林,等.细胞因子的研究进展及其应用,动物科学与动物医学 2004.21(10):10-12.
[42]金伯泉.细胞和分子免疫学[M].北京:科学出版社,2001,131-239
[43]Ryu D D,Nam D H.Recent progress in biomolecular engineering[J].Biotechnol Prog,2000,1(1):2-16
[44]Morgan R A,Anderson N.Human gene therapy.Annu Rev Biochem,1993,2:191-204
[45]Schijns V E,Classen I J.Vermeulen A A,et al.Modulation of antiviral immune responses by exogenous cytokines:effects of tumour necrosis factor alpha,interleukin-1 alpha,interleukin-2 and interferon-gamma on the immunogenictiy of an inactivated rabies vaccine[J],J Gen Virol,1994,75(1):55-63
[46]Sasaki M G,Foccacia R,Messias-Reason I J.Efficacy of granulocyte-macrophage colony-stimulating factor(GM-CSF)as a vaccine adjuvant for hepatitis B virus in patients with HIV infection[J].Vaccine,2003,21(31)4545-4549
[47]Auccoutorier J,Dupuis L,Ganne Y.Adjuvants designed for veterinary and human vaccines[J].Vaccine,2001,19(17-19):2666-2672
[48]Playfair H L and Desouza J B. Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice. Clinical Experimental Immunology. 1987, 67:5-10
[49]Heath AW, Playfair JH. Conjugation of interferon-gamma to antigen enhances its adjuvanticity [J]. Immunology. 1990, 71(3):454-456.
[50]SinJL, Kim JJ, Boyer J D, et al. In vivo modulation of vaccine-induced immune response toward a Thl phenotype increases potency and vaccine effedctiveness in a herpes simplex virus type2 mouse model . J Virol. 1999, 73:501—507
[51]Micallef MJ, Ohtsuki K, Kohno F, et al. Interferon-gamma-inducing factor enhances T helper lcytokine production by stimulated human T cell: Synergi-sm with interleukin-12 for interferon-gamma production [J].Eur J Immunol, 1996, 2(7):1647-1651
[52]Guidotti LG, Huang W K, et al. Improvement of hepatitis B virus DNA vaccines by plasmid co-expressing hepatitis B surface antigen and interleukln-18. Hepato- logy, 1998, 28:202-210
[53] Chow YH Chiang BL, Lee YL, et al. Development of Thl and Th2 population and the nature of immune responses to hepatitis B virus DNA vaccines can be. modulated by code livery of various cytokine genes, J Immunol, 1998, 160:1320-1329
[54]Iwasaki A, Stiernholm B J, Chan A K, et al, Enhancee CTL responses mediated by plasmid DNA immunogenes encoding costimulatory moleculars and cytokines[J], J Immunol, 1997, 158(10):4591-4601
[55]Sin J I, Weiner D B. Improving DNA vaccines targeting viral infection [J]. Interv -irology, 2000, 43(4-6)233-246
[56]Billaut-mulot 0, IdriorekT, Loyens M, et al. Modulation of cellular and humoral immune responses to a multipitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost[J]. Vaccine, 2001, 19(20-22):2803-2811
[57]Kimm JJ,Yang J S, Vcncort T C, et al.Modulation of antigen-specific humoral responses in Rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants [J].J, Virol, 2000, 74(7):3427-3429
[58]Barouch, D H: Santra, S. Steenbeke, T. D et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. Journal of Immunology(Baltimore).1998.161:1875-1882.
[59]蔡雷.DNA免疫的基础性研究进展及应用.国外医学免疫学分册,2001,24:122-125
[60]文艳君.增强DNA免疫效应的研究进展.国外医学免疫学分册,1999,22:320-323
[61]lrvine K R,RaoJB,Rosenberg S A.et al.Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.J Immunol,1996,156:238-245
[62]Yang S et al.Generation of retroviral vector for clinical studies using transient transfection.Hum Gene Ther,1999 Jan 1;10(1):123-32
[63]Doughrety JP et al.High mutation rate of a spleen necrosis virus-based retrovirus vector.Mol Cell Biol,1986;12:4387
[64]Louis MH et al.Internal ribosome entry sites(IRESs):reality and use.Transgrnic Res,1999;8:157
[65]J.萨姆布鲁克,E.F.弗单奇,T.曼尼阿蒂斯.分子克隆实验指南第二版[M].会冬雁,黎孟枫,译.北京:科学出版社,1992.
[66]Flasshove M et al.Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene.J Cancer Res Clinoncol,2000;126:391
[67]Martinez-Salas E,Quinto S L,and Ramos R,and Fernandez-Miragall O.IRES elements:features of the RNA structure contributing to their activity.BiOchimie,2002,84:755-763.
[68]Michael E et al.Comparison of promoter suppression in avian and murine retrovirus vectors.Nucleic Acids Res,1986;23:9381
[69]刘兵等.中国生化与分子生物学报,1999;15:699
[70]Medina E,Paglia P,Nikolaus T,et al.Pathogenicity is land-mutants of Salmonella typhi murium are efficient carriers for heterologous antigens and enable modulation of immune responses.Infect Immunity,1999,67(3):1093-1099.
[71]Urashima M,Suzuki H,Yuza Y,et al.An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhi murium.Blood,2000,95(4):1258-1263.
[72]Shiau AL,Chen YL,LiaoCY et al.Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis [J]. Vaccine,2001,19:3947-3956
[73]Sydenham M, Douce G, Bowe F, et al. Salmonella enterica serovar typhimurium surA mutants are attenuated and effective live oral vaccines[J]. Immunol, 2000, 68(3):1109-1115.
[74]Ministry of Agriculture Veterinary Biological Product Regulation Committee Compiled. The People's Republic of China Veterinary Biological Product Regulation, Beijing: ChemicalIndustry Publishing Company. 2000,pp. 164-166
[75]Dietrich G, Spreng S, Gentschev I et al. Bacterial systems for the delivery of eukary oticantigen expression vectors. Antisense NucleicAcid Drug Dev , 2000 , 10(5):391-399
[76]Hone D M. Harris A M. Chatfield S et al. Construction of genetically defined double are mutant of Salmonella typhimurine. Vaccine, 1991, 9(11):810-816.
[77]Attridge S R, Davies R, Labrooy J T. Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Vaccine. 1997, 15(2):155-162.
[78]Shata M T ,Stevceva L ,Agwale S ,et al.Recent advances with recombinant bacterial vaccine vectors (J) .Mol Med Today ,2000, 6 (2) :66-71.
[79]Roy Curtiss III. Bacterial infectious disease control by vaccine development. J.C1in. Invest. 2002, 110:1061-1066.
[80]Emil Kozarov , Naohisa Miyashita , Jacob Burks et al. Expression and Immunogenicity of Hemagglutinin A from Porphyromonas gingivalis in an Avirulent Salmonella enterica Serovar Typhimurium Vaccine Strain. Infection and Immunity, 2000, 2(68):732-739.
[81]PagliaP, Terrazzini N, SchulzeK, Guzman CA, Colombo MP. In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery. Gene Ther 2000, 10, 7(20), 1725-1730.
[82]Kohno K, Kataoka J, Ohtsuki T, et al. IFN-gamma-in-ducing factor(IGIF)is a costimulatory factor on the activation of Thl but not Th2 cells and exertsits effect in-dependently of IL-12 [J] J Immunol, 1997, 158(4):1541-1550
[83]Toka F N,Pack C D,and Rouse B T.Molecular adjuvants for mucosal immunity.ImmunolOgical Reviews,2004,199:lO0-112
[84]Dietrich G,Spreng S,Gentschev I,et al.Bacterial systems for the delivery of eukaryotic antigen expression vectors[J].Antisense Nucleic Acid Drug Dev 2000,10(5):391-399.
[85]Hormaeche C E.Live attenuated Salmonella vaccines and their potential as oral combined vaccines carrying heterologous antigens[J].J Immunol Methods,19,142(1):113-120.
[86]Toebe CS,et al.Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1[J]Am J Trop Med Hyg,1997,56:192.
[87]Somner EA,et al.Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains[J]Microbiol,1999,145:221.
[88]Okamura H,Nagate K,Komatsu T,A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock[J].Infect Immun,1995,63(10):3966-3972
[89]Hilton LS,Bean AG,Lowenthal JW.The emerging role of avian cytokines as immuneotherapeutics and vaccine adjuvants[J].Vet Immunol immunopathol,2002,85(3-4):119-128
[90]洪云平,文心田.细胞因子及其在兽医上的应用[J].预防兽医学进展,2000,2(2):4-7
[91]Wood P R,Seow H F.T cell cytokines and diseases prevention[J].Vet Immunol Immunopathol,1996,54,33-44.:
[92]Johnson M A,Pooley C,Lowenthal J W.Delivery of avian cytokines by adenovirus vectors.Dev Comp Immunol,2000,24:343-354
[93]Lowenthal J W,York J J,O' Nell T E,Rhodes S,Prowse S J,Strom A D G,Digby M R.In vivo effects of chicken interferon gamma during infection with Eimeria.J Interferon Cytokine Res,1997,17:551-558
[94]Marcus P I,vander Heide L,Sekellick M J.Interferon action on avian viruses.I.Oral administration of chicken interferon-alpha ameliorates Newcastle disease.J Interferon Cytokine Res,1999,19:881-885
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |